Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.58 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.58 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.58 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.58 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.58 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.58 |
| ▸ | NMT1 | P30419 | 4/20 | 0.56 |
| ▸ | NMT2 | O60551 | 1/20 | 0.56 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | GABRP | O00591 | 1/20 | 0.52 |
| ▸ | GABRD | O14764 | 1/20 | 0.52 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11551727 | 0.88 | MEN1 (0.61) | MMP13MEN1HSP90AA1KMT2AGABRA1 | |
| SCHEMBL689328 | 0.84 | KDM4E (0.61) | MMP13ALDH1A1HPGDMAPTLMNA | |
| SCHEMBL8200870 | 0.81 | ALDH1A1 (0.54) | GABRA1GABRA3ALDH1A1HPGDMAPT | |
| SCHEMBL8199577 | 0.81 | ALDH1A1 (0.57) | MMP13MEN1KMT2AGABRA1GABRG2 | |
| SCHEMBL13343442 | 0.81 | ALDH1A1 (0.54) | MEN1KMT2AALDH1A1HPGDMAPT | |
| SCHEMBL4932631 | 0.81 | MMP13 (0.58) | MMP13ALDH1A1HPGDLMNAKDM4E | |
| SCHEMBL689369 | 0.80 | KDM4E (0.55) | ALDH1A1HPGDMAPTLMNAL3MBTL1 | |
| SCHEMBL30782682 | 0.80 | BRD4 (0.55) | MMP13MEN1KMT2AGABRA1GABRG2 | |
| SCHEMBL689576 | 0.80 | BRD4 (0.55) | MMP13MEN1KMT2AGABRA1GABRG2 | |
| SCHEMBL4933923 | 0.79 | ALDH1A1 (0.52) | MMP13GABRA1GABRG2GABRB3GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9475822-B2 | Substituted 2- amidoquinazol-4-ones as matrix metalloproteinase-13 inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-10-25 | — | — | US | disclosed |
| US-9212149-B2 | Substituted 2-amidoquinazol-4-ones as matrix metalloproteinase-13 inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-12-15 | — | — | US | disclosed |
| US-20150329556-A1 | SUBSTITUTED 2- AMIDOQUINAZOL-4-ONES AS MATRIX METALLOPROTEINASE-13 INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2015-11-19 | — | — | US | disclosed |
| EP-1740551-B9 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF AS AN MMP-13 INHIBITOR | TAKEDA PHARMACEUTICAL (JP) | 2013-01-16 | — | — | EP | disclosed |
| EP-1740551-B1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF AS AN MMP-13 INHIBITOR | TAKEDA PHARMACEUTICAL (JP) | 2012-09-12 | — | — | EP | disclosed |
| US-20080027050-A1 | Heterocyclic Amide Compound and Use Thereof as an Mmp-13 Inhibitor(Amended Ex Officio) | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-31 | — | — | US | disclosed |
| EP-1740551-A1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF AS AN MMP-13 INHIBITOR | Takeda Pharmaceutical Company Limited (JP) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005105760-A1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF AS AN MMP-13 INHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329556-A1 | SUBSTITUTED 2- AMIDOQUINAZOL-4-ONES AS MATRIX METALLOPROTEINASE-13 INHIBITORS | MMP13, MMP14, MMP25 | MMP13 1/4885MEN1 3012/4885HSP90AA1 3972/4885 |
| US-20080027050-A1 | Heterocyclic Amide Compound and Use Thereof as an Mmp-13 Inhibitor(Amended Ex Officio) | MMP13, HDAC11, HDAC1 | MMP13 1/4885MEN1 3549/4885HSP90AA1 3560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.